Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Ionis Highlights Transformational RNA Medicines, $2B Cash Position, And Two More Independent Launches Planned For 2026

Author: Benzinga Newsdesk | October 07, 2025 07:17am

Two independent launches underway in less than nine months, with two more on track for 2026
Growing pipeline of wholly owned medicines in neurology and cardiometabolic disease and leading technology for next-generation medicines
Clear path to sustained positive cash flow

Posted In: IONS